How do target of rapamycin inhibitors (TOR-I) compare with antimetabolites (AM) for primary immunosuppression in kidney transplant recipients?
2008 ◽
Vol 8
(7)
◽
pp. 1384-1392
◽
2016 ◽
Vol 31
(8)
◽
pp. 1360-1367
◽
2010 ◽
Vol 42
(9)
◽
pp. S41-S43
◽
2011 ◽
Vol 12
(2)
◽
pp. 379-387
◽
2014 ◽
Vol 14
(9)
◽
pp. 2106-2119
◽